"Drug Repositioning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The deliberate and methodical practice of finding new applications for existing drugs.
| Descriptor ID |
D058492
|
| MeSH Number(s) |
E05.295.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Repositioning".
Below are MeSH descriptors whose meaning is more specific than "Drug Repositioning".
This graph shows the total number of publications written about "Drug Repositioning" by people in this website by year, and whether "Drug Repositioning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 1 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Repositioning" by people in Profiles.
-
Freidel MR, Armen RS. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike. Viruses. 2024 04 30; 16(5).
-
Ponzini FM, Schultz CW, Leiby BE, Cannaday S, Yeo T, Posey J, Bowne WB, Yeo C, Brody JR, Lavu H, Nevler A. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma. BMJ Open. 2023 10 17; 13(10):e073839.
-
Onoufriadis A, Proudfoot LE, Ainali C, Torre D, Papanikolaou M, Rayinda T, Rashidghamat E, Danarti R, Mellerio JE, Ma'ayan A, McGrath JA. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing. Exp Dermatol. 2022 03; 31(3):420-426.
-
Chen A, Patel S, Alcusky M, Maio V. Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts? Am J Med Qual. 2021 Mar-Apr 01; 36(2):122-124.
-
Sharma P, McAlinden KD, Ghavami S, Deshpande DA. Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? Eur J Pharmacol. 2021 Apr 15; 897:173928.
-
Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020 08; 20(4):414-420.
-
Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, Muyembe TamFum JJ, Seydi M, Eholie SP, Mills EJ, Kallay O, Zumla A, Nachega JB. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med Hyg. 2020 06; 102(6):1184-1188.
-
Napper AD, Mucke HA. A Special Focus on Drug Repurposing, Rescue, and Repositioning. Assay Drug Dev Technol. 2015 Jul-Aug; 13(6):293.